HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00

Century Therapeutics (NASDAQ:IPSC - Free Report) had its price objective reduced by HC Wainwright from $9.00 to $5.00 in a research note published on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

Separately, Rodman & Renshaw initiated coverage on shares of Century Therapeutics in a research note on Thursday, August 8th. They set a "buy" rating and a $6.00 target price for the company.

Century Therapeutics Stock Up 4.5 %

Shares of IPSC stock traded up $0.06 during trading on Wednesday, reaching $1.39. The company had a trading volume of 525,941 shares, compared to its average volume of 334,993. Century Therapeutics has a one year low of $1.14 and a one year high of $5.51. The firm's 50 day simple moving average is $1.53 and its two-hundred day simple moving average is $2.24.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The firm had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.47 million. Century Therapeutics had a negative net margin of 6,434.23% and a negative return on equity of 60.60%. During the same quarter in the previous year, the business earned ($0.55) EPS. As a group, research analysts predict that Century Therapeutics will post -1.8 EPS for the current year.

Institutional Trading of Century Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. raised its position in Century Therapeutics by 191.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 293,941 shares of the company's stock worth $1,229,000 after purchasing an additional 192,915 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Century Therapeutics by 110.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company's stock worth $380,000 after buying an additional 78,088 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Century Therapeutics by 141.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company's stock worth $192,000 after buying an additional 44,155 shares during the period. Rhumbline Advisers boosted its stake in Century Therapeutics by 56.0% in the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company's stock valued at $134,000 after buying an additional 18,828 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Century Therapeutics in the third quarter valued at $27,000. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.